Latest News & Features
Americas
Shionogi and Concordia Pharmaceuticals sued Hi-Tech Pharmacal yesterday for allegedly infringing patents centring on the drug Ulesfia, an anti-parasite medication. 9 August 2016
Americas
NuScience, a US based nutritional supplement company, has asked a court to imprison two brothers who are at the centre of a trade secrets lawsuit. 9 August 2016
Americas
The US and China take very different approaches to the patentability of a range of inventions in the life sciences field, as Yu Guo of China Patent Agent reports. 9 August 2016
Americas
AstraZeneca has sued Mylan for allegedly infringing its patents covering the drug Faslodex. 8 August 2016
Americas
AbbVie has sued Amgen saying its proposed biosimilar for the Humira (adalimumab) drug infringes 61 patents. 8 August 2016
Asia-Pacific
A new fund dedicated to accelerate the development and commercialisation of Australian biomedical discoveries has officially launched. 5 August 2016
Americas
Fustibal, a targeted therapeutics biotechnology start-up, has filed an inter partes review petition challenging a patent owned by German pharmaceutical company Bayer. 4 August 2016
Americas
Editas Medicine, a US genome-editing company, announced yesterday that it has entered into an exclusive licensing agreement with Massachusetts General Hospital to access CRISPR technology. 4 August 2016
Americas
Natco Pharma, an India-based drugs company, announced today that it has received final approval from the US Food and Drug Administration to produce a generic version of Tamiflu. 4 August 2016
Americas
Inter-partes reviews (IPRs) can be a powerful weapon against patents listed in the Orange Book. However, IPR practice favours a petitioner who has carefully thought about the issues and crafted the best strategy, says Mark Remus of Brinks Gilson & Lione. 4 August 2016